The Perils of Ignoring Negative Data

Today, Eleven Biotherapeutics (NASDAQ:$EBIO) announced the failure of its Phase 3 trial of an IL1 receptor antagonist in dry eye.   The company indicated they saw no way forward for the product candidate in this indication, which with a little translation, indicates a comprehensive failure of the study (rather than a near-miss on the primary end-point, for example). Unsurprisingly, the company lost most (-69% as at 4.20pm EDT) of its value as a result.

from Forbes – Business
via Abogado Aly Business Consulting

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s